To carry out their activities, Research Teams of the Frédéric Joliot Institute for Life Sciences have developed high-profile technological platforms in many areas : biomedical imaging, structural biology, metabolomics, High-Throughput screening, level 3 microbiological safety laboratory...
Within the Institute, the "Funding Research and Technology Transfer" team is at your disposal to identify the scientists and the skills you need to set up a joint project, to define the terms of a collaboration contract or study.
Whether you are an academic, a SME or an industrialist, our team informs and advices you about the possibilities of consortium assembly, technology transfer, patent licensing or use of our platforms.
The team is also at the disposal of the researchers of the institute to accompany them in achieving their valorization objectives.
All the news of the Institute of life sciences Frédéric Joliot
European ＆ international partnerships
Involvement of the Institute of life sciences Frédéric Joliot in EU programmes.
NOMATEN, same acronym for a European project (CSA teaming) and a center of excellence (CoE). NOMATEN is a support and coordination action (EC H2020 Teaming Phase 2 program, grant agreement 857470) aiming to accompany the NCBJ (National Center for Nuclear Research, Świerk, Poland) in the construction and ramp-up of a center of excellence (CoE) of the same name, on innovative multifunctional materials for industrial and medical applications. http://nomaten.ncbj.gov.pl/
FLIX FLow chemistry for Isotopic eXchangeFLIX is a radically new concept for the ultimate-stage chemical isotopic labeling of high added-value molecules (drugs, biologics, smart materials) with stable isotopes (2H, 13C, 15N). It utilizes the unique properties of new generations of catalysts, which specifically and selectively exchange predetermined atoms and chemical motifs of end-use organic compounds. The ultimate outcome of the project is to devise and build a modular and adaptable flow chemistry system for the straightforward and combinable isotopic labeling of complex chemicals and biologics. The project is expected to have a multi-billion Euro positive impact on all sectors using stable isotopes in particular: 1) drug innovation, by accelerating preclinical studies, de-risking clinical trials and fostering the development of novel deuterated 'heavy drugs'; 2) design of new tracers for diagnostic imaging with improved biological properties; 3) streamlining the production of multi-labeled complex molecules for NMR studies; 4) the development of novel isotopically enriched materials.http://flix-h2020.eu/
MICROB-PREDICTMicrob-Predict aims to better understand the role of the microbiome in the evolution of cirrhosis of the liver and its interaction with drugs. This project is part of a personalized medicine approach for a better stratification of patients. The CEA/SPI will perform metabolomic analyzes.
The R-LINK project aims to
develop and validate a stratified approach to improve the care of patients
suffering from bipolar disorders and treated with lithium. As a first step, our
goal is to set up and exploit a multimodal database combining MRI, lithium-7
MRI, and blood "omic" biomarkers to define a predictive signature of
the positive response to lithium. Our researchers are participating in this
ambitious project because of their expertise in very high magnetic field
imaging, statistics applied to biomedical research and multimodal database
management. NeuroSpin's MRI 7T will be used to characterize the
distribution of lithium in the human brain. These results will build a
multidisciplinary network of international experts to define new diagnostic and
therapeutic approaches to personalized medicine.
Imaging has become multimodal and multiparametric : it combines the benefits of multiple technologies to create new, more accurate images that carry more anatomical, molecular and functional information. This modern imaging makes it possible to better characterize the specificities of each patient and to evolve towards what is commonly called by the European Commission "Personalized Medicine". The optimal exploitation of the potential of this new imaging requires a new generation of experts trained in this integration of technologies: this is the goal of the innovative Hybrid training network that brings together a consortium of academic centers and industrial experts in multimodal imaging, from sensor design to image analysis in order to extract original biomarkers guiding personalized medicine.More information at Hybrid website.
Using current biotoxin best practices, members of the
EuroBioTox consortium will develop and validate improved analytical tools, reagents and standard operating procedures based on realistic incident scenarios. Certified reference materials will be developed against this threat and, by establishing a European database, will be made available to the
EuroBioTox network, comprising more than 50 European organizations.
ABACUS aims to develop a technology-oriented, business-oriented seaweed biorefinery, bringing to the market innovative seaweed-based ingredients for high-end applications ranging from seaweed terpenes for fragrance terpenoid long chain (carotenoids) for nutraceuticals and cosmetics.https://www.abacus-bbi.eu/
ZIKAlliance, a multinational and multidisciplinary research consortium will study the clinical, fundamental, environmental and social aspects of Zika virus infection. In particular,
ZIKAlliance will focus on the impact of Zika virus infection during pregnancy and the natural history of Zika virus in humans and their environment. In collaboration with two other consortia funded by the EC (ZikaPLAN and ZIKAction),
ZIKAlliance will also work on the development of an intervention platform in Latin America and the Caribbean.
The objective of DiamESTar is to evaluate the efficacy of a new siRNA / nanocarrier complex to treat metastatic tumors of Ewing's sarcoma (SE), when this complex is associated with a Fab antibody fragment directed against a membrane protein, overexpressed in the cells.
M-CUBEM-Cube aims at changing the paradigm of High-Field MRI and Ultra High-Field antennas to offer a much better insight on the human body and enable earlier detection of diseases. Our main objective is to go beyond the limits of MRI clinical imaging and radically improve spatial and temporal resolutions. The clinical use of High-field MRI scanners is drastically limited due to the lack of homogeneity and to the Specific Absorption Rate (SAR) of the Radio Frequency (RF) fields associated with the magnetic resonance.
CEA is a French government-funded technological research organisation in four main areas: low-carbon energies, defense and security, information technologies and health technologies. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world.